Biological Information
Background Information:
ADCP is the mechanism by which antibody-opsonized target cells activate the FcγRs on the surface of macrophages to induce phagocytosis, resulting in internalization and degradation of the target cell through phagosome acidification. In the KILR Daudi ADCP Bioassay, ready-to-use KILR Daudi target cells expressing the antigens of interest are co-incubated with macrophages and an opsonizing therapeutic antibody for 24 hours. In this assay, KILR Daudi target cells endogenously expressing the desired antigen (e.g. CD19, CD20 or CD38) were engineered to stably express a housekeeping protein that is tagged with enhanced ProLabel® (ePL), a β-gal reporter fragment. These KILR Daudi target cells will be phagocytosed by macrophages during the process of ADCP. The remaining target cells in the co-culture are lysed in the presence of PathHunter® PL/PK Detection reagent kit which includes the EA fragment of β-gal enzyme, and enzyme substrate, resulting in complementation of any remaining KILR reporter protein in which produces a functional β-galactosidase enzyme, which generates a chemiluminescent signal that can be detected on any benchtop luminescence reader.
Target Species:
Human
Cell Background:
Daudi
Usage
Product Type:
Bioassay Kits
Application:
Potency, Commercial Release & Stability
Kit Components:
Storage Conditions:
Store in vapor phase of liquid nitrogen.
Usage disclaimer:
These products may be covered by issued US and/or foreign patents, patent applications and subject to a Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information.
Assay Information
Assay Type:
Cell Based
Assay Measures:
Cytotoxicity
Detection Method:
Chemiluminescence
Clinical Relevance
Therapeutic Area:
Oncology/Immuno-Oncology
Additional Information
Brand:
KILR®